Learn about our healthcare areas

Explore medicine and therapy products
Explore MedTech products

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. Home/
      2. Media Center/
      3. Press releases /
      4. Innovative Medicine

      Innovative Medicine

      Innovative Medicine
      December 5, 2017

      Phase 3 Study Evaluating IMBRUVICA® (ibrutinib) in Combination with Rituximab in Waldenström’s Macroglobulinemia Met Primary Endpoint

      Learn more
      Innovative Medicine
      November 30, 2017

      Johnson & Johnson and Partners Announce First Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

      Learn more
      Innovative Medicine
      November 21, 2017

      Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection

      Provides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1
      Learn more
      Innovative Medicine
      November 21, 2017

      Janssen Submits Application to U.S. FDA to Expand Indication for DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma who are Transplant Ineligible

      Learn more
      Innovative Medicine
      November 17, 2017

      New Real-World Analysis Shows INVOKANA® (canagliflozin) and Other SGLT2 Inhibitors Reduced the Risk of Death and Cardiovascular Events Compared to Other Diabetes Medicines

      Learn more
      Innovative Medicine
      November 14, 2017

      INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

      Learn more
      Innovative Medicine
      November 7, 2017

      NEW PHASE 2 DATA SHOW TREATMENT WITH TREMFYA® (GUSELKUMAB) IMPROVED PSORIATIC ARTHRITIS SYMPTOMS THROUGH ONE YEAR

      Longer-Term Results Demonstrate Continued Efficacy of Anti-Interleukin 23 Monoclonal Antibody TREMFYA® in Improving Joint and Skin Symptoms Associated with Active Psoriatic Arthritis
      Learn more
      Innovative Medicine
      November 6, 2017

      STELARA® (USTEKINUMAB) SHOWS POSITIVE RESULTS IN TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN PHASE 2 TRIAL

      Learn more
      Innovative Medicine
      November 3, 2017

      INVOKANA® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease

      Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting
      Learn more
      Load More